On April 12, 2020, the Wuhan Institute of Biological Products under Sinopharm CNBG became the world's first facility to receive Phase I and II clinical trial approval for inactivated COVID-19 vaccines.
Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, Beijing
Postcode: 100191
Tel: 86-10-82287727
Fax: 86-10-62033332
Links:
Member companies
- Sinopharm Group Co Ltd (Sinopharm Holding)
- China National Biotec Group Company Ltd
- China State Institute of Pharmaceutical Industry
- China Sinopharm International Corporation
- Reed Sinopharm Exhibitions Co Ltd
- China Traditional Chinese Medicine Holdings Co Ltd
- Shanghai Shyndec Pharmaceutical Co Ltd
- Sino Pharmengin Corporation
- China National Pharmaceutical Investment Co Ltd
- Sinopharm Group Finance Co Ltd
- China National Medicines Corporation Ltd
- China National Accord Medicines Corporation Ltd
- Beijing Tiantan Biological Products Co Ltd
- Chongqing Taiji Industry (Group) Co Ltd
Joint ventures
Associations
- China Pharmaceutical Industry Association
- China National Narcotic Drugs Association
- China Association of Pharmaceutical Commerce
- China Pharmaceutical Innovation and Research Development Association
- China Association of Medicine Devices Industry
- China Association of Traditional Chinese Medicine
- China Pharmaceutical Culture Society
Government departments
Copyright © China National Pharmaceutical Group Co Ltd.
All rights reserved. Presented by China Daily. 京公网安备 11040102700104号 京ICP备：14023670号-1
